These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16604825)

  • 61. Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report.
    Hayashi T; Morishita E; Ontachi Y; Yamazaki M; Asakura H; Yoshida T; Nakao S
    Am J Hematol; 2006 Feb; 81(2):121-3. PubMed ID: 16432874
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate.
    Saini HK; Sharma SK; Zahradka P; Kumamoto H; Takeda N; Dhalla NS
    Can J Physiol Pharmacol; 2003 Nov; 81(11):1056-63. PubMed ID: 14719041
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.
    Hamasaki Y; Doi K; Maeda-Mamiya R; Ogasawara E; Katagiri D; Tanaka T; Yamamoto T; Sugaya T; Nangaku M; Noiri E
    Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1796-803. PubMed ID: 24107419
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries.
    Kong D; Melo LG; Gnecchi M; Zhang L; Mostoslavsky G; Liew CC; Pratt RE; Dzau VJ
    Circulation; 2004 Oct; 110(14):2039-46. PubMed ID: 15451799
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sarpogrelate treatment reduces restenosis after coronary stenting.
    Fujita M; Mizuno K; Ho M; Tsukahara R; Miyamoto A; Miki O; Ishii K; Miwa K
    Am Heart J; 2003 Mar; 145(3):E16. PubMed ID: 12660685
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of sarpogrelate on cardiomyocyte hypertrophy.
    Ikeda K; Tojo K; Tokudome G; Hosoya T; Harada M; Nakao K
    Life Sci; 2000 Nov; 67(24):2991-6. PubMed ID: 11133011
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
    Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials.
    Lu Y; Li J; Xie J; Yu Q; Liao L
    Medicine (Baltimore); 2019 Nov; 98(46):e17266. PubMed ID: 31725602
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of 5-HT2A receptor antagonist on blood flow in chronically compressed nerve roots.
    Sekiguchi M; Konno S; Kikuchi S
    J Peripher Nerv Syst; 2004 Dec; 9(4):263-9. PubMed ID: 15574139
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.
    Yoshimasu T; Ikeda T; Uede K; Kanazawa N; Furukawa F
    J Dermatol; 2012 Jun; 39(6):536-40. PubMed ID: 22077618
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [2-(O-Phenylalkyl)phenoxy]alkylamines III: Synthesis and selective serotonin-2 receptor binding (2).
    Tanaka N; Goto R; Ito R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
    Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1729-39. PubMed ID: 11086903
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Platelets as participants in hyperacute guinea pig-to-rat lung xenorejection.
    Nonaka M; Kadokura M; Kataoka D; Yamamoto S; Tanio N; Inoue K; Takaba T
    Surg Today; 1999; 29(3):255-9. PubMed ID: 10192737
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sarpogrelate hydrochloride, an antagonist of 5-hydroxytryptamine receptor, improves skin flap survival and suppresses thrombus formation in injured microvessels of rabbits.
    Takase MT; Hashimoto I; Nakanishi H; Nakaya Y; Harada H; Sedo H; Kanda I
    J Reconstr Microsurg; 2006 Jan; 22(1):59-65. PubMed ID: 16425124
    [TBL] [Abstract][Full Text] [Related]  

  • 75. LY53857, a 5HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion.
    Wilson HC; Coffman W; Killam AL; Cohen ML
    Thromb Haemost; 1991 Sep; 66(3):355-60. PubMed ID: 1746008
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease.
    Horibe E; Nishigaki K; Minatoguchi S; Fujiwara H
    Circ J; 2004 Jan; 68(1):68-72. PubMed ID: 14695468
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans.
    Yamakawa J; Takahashi T; Saegusa S; Moriya J; Itoh T; Kusaka K; Kawaura K; Wang XQ; Kanda T
    J Int Med Res; 2004; 32(2):166-9. PubMed ID: 15080020
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapeutic potentials of sarpogrelate in cardiovascular disease.
    Saini HK; Takeda N; Goyal RK; Kumamoto H; Arneja AS; Dhalla NS
    Cardiovasc Drug Rev; 2004; 22(1):27-54. PubMed ID: 14978517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combinational Use of Antiplatelet Medication Sarpogrelate with Therapeutic Drug Rosuvastatin in Treating High-Cholesterol Diet-Induced Chronic Kidney Disease in ApoE-Deficient Mice.
    Xu J; Pei Z; Yu M; Li X; Wang L; Lin Y; Chen X; Liu X
    Biomed Res Int; 2020; 2020():1809326. PubMed ID: 33029491
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sarpogrelate: cardiovascular and renal clinical potential.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jul; 13(7):865-74. PubMed ID: 15212624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.